SUBSTANCE DEPENDENT TEENS--IMPACT OF TREATING DEPRESSION

物质依赖青少年——治疗抑郁症的影响

• 批准号: 6653679
• 负责人: Paula DeGraffenreid Riggs
• 金额: $ 6.2万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6653679
• 关键词: adolescence (12-20); behavioral /social science research tag; clinical research; clinical trials; cognitive behavior therapy; combination therapy; comorbidity; conduct disorder; fluoxetine; human subject; human therapy evaluation; major depression; mental disorder chemotherapy; substance abuse related disorder; therapy compliance

DESCRIPTION: (Applicant's Abstract) Adolescents with substance use disorders (SUD) and conduct disorder (CD) have high rates of comorbid depression. Despite the high prevalence of depression in such youth, little is known about effective treatment of such depressions. Moreover, the effects of treating depression on substance use and other problem behaviors in such youth are not known. Only serotonergic agents, fluoxetine (FLX) and paroxetine, with most support for FLX, have empirical support in the treatment of depression in adolescents without serious comorbidity. It is not known whether FLX (or paroxetine) are effective in treating the depressions of adolescents with SUD and CD. The proposed study is a randomized, placebo-controlled trial comparing placebo to fluoxetine for major depressive disorder (MDD) in 120 adolescents with SUD and CD. Adolescents with DSM-1V SUD, CD, and MDD assessed both clinically and with structured assessment instruments, will be randomized to one of these two treatment cells for 16 weeks. All subjects will also receive standardized, manual-driven cognitive behavior treatment for adolescent SUD for the duration of the trial as the background "treatment as usual" Medication compliance will be electronically monitored. Adverse side effects will be monitored weekly. The specific aims of this study are to test the following hypotheses: 1. Fidoxeline + CBT will be more effective in treating unipolar depression in adolescents with SUD and CD than placebo + CBT. 2. The treatment of depression with RX + CBT, in depressed adolescents with SUD and CD will be more effective than placebo + CBT in reducing substance use and improving conduct symptoms. 3. The treatment of depression with RX will result in greater retention in, and compliance with substance treatment (CBT) and reduction in both substance use and conduct problems than treatment with placebo. This research will contribute important knowledge regarding effective treatment of depression in conduct-disordered adolescents with SUD and provide information about the effects of treating depression on substance and other behavioral outcomes as well.

描述：（申请人摘要） 患有物质使用障碍 (SUD) 和品行障碍 (CD) 的青少年 共病抑郁症的发生率很高。尽管抑郁症患病率很高 对于这样的年轻人，人们对此类抑郁症的有效治疗知之甚少。 此外，治疗抑郁症对物质使用和其他问题的影响 这些年轻人的行为尚不清楚。仅血清素能药物氟西汀 （FLX）和帕罗西汀，对 FLX 的支持最多，在 治疗没有严重合并症的青少年抑郁症。它不是 已知FLX（或帕罗西汀）是否能有效治疗抑郁症 患有 SUD 和 CD 的青少年。拟议的研究是一项随机、 比较安慰剂与氟西汀治疗重度抑郁症的安慰剂对照试验 120 名患有 SUD 和 CD 的青少年患有 MDD。患有 DSM-1V SUD 的青少年， CD 和 MDD 通过临床和结构化评估进行评估 仪器，将被随机分配到这两个治疗单元之一，持续 16 几周。所有受试者还将接受标准化、手动驱动的认知 试验期间青少年 SUD 的行为治疗作为 背景“照常治疗” 药物依从性将以电子方式进行 被监控。将每周监测不良副作用。具体目标 本研究旨在检验以下假设： 1. Fidoxeline + CBT 将 治疗患有 SUD 和 CD 的青少年单相抑郁症更有效 比安慰剂+CBT。 2. RX+CBT治疗抑郁症，在抑郁症中 患有 SUD 和 CD 的青少年比安慰剂 + CBT 更有效 减少物质使用并改善行为症状。 3.治疗 RX 的抑郁症将导致更大的保留和依从性 物质治疗（CBT）以及减少物质使用和行为 与安慰剂治疗相比出现的问题。这项研究将做出重要贡献 关于有效治疗行为障碍抑郁症的知识 患有 SUD 的青少年并提供有关治疗效果的信息 对物质和其他行为结果的抑郁。